Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: A frequentist meta-analysis approach

New Microbiologica

Volumn 37, Issue 3, 2014, Pages 263-276

  Lanini, Simone ^a   Mammone, Alessia ^a   Puro, Vincenzo ^a   Girardi, Enrico ^a   Bruzzi, Paolo ^b   Ippolito, Giuseppe ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Adverse event; Boceprevir; Direct acting antiviral compounds; Experienced patients; Hepatitis C infection; Iatrogenic disease; Na ve patients; Opportunistic infection; Sustained virological response; Telaprevir

Indexed keywords

ANTIVIRUS AGENT; OLIGOPEPTIDE; RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ANEMIA; ARTICLE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; YOUNG ADULT;

EID: 84906489796     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., Guyatt G.H., Harbour R.T., Haugh M.C., Henry D., Hill S., Jaeschke R., Leng G., Liberati A., Magrini N., Mason J., Middleton P., Mrukowicz J., O'Connell D., Oxman A.D., Phillips B., Schünemann H.J., Edejer T., Varonen H., Vist G.E., Williams J.W., Zaza S. (2004). Grading quality of evidence and strength of recommendations. BMJ. 328, 1490.
2. Bassler D., Briel M., Montori V.M., Lane M., Glasziou P., Zhou Q., Heels-Ansdell D., Walter S.D., Guyatt G.H. (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 303, 1180-1187.
3. Berlin J.A., Longnecker M.P., Greenland S. (1993). Meta-analysis of epidemiologic dose-response data. Epidemiology. 4, 218-228.
4. Chak E., Talal A.H., Sherman K.E., Schiff E.R., Saab S. (2011). Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 31, 1090-1101.
5. Chou R., Hartung D., Rahman B., Wasson N., Cottrell E.B., Fu R. (2013). Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann. Intern. Med. 158, 114-123.
6. Chou R., Hartung D., Rahman B., Wasson N., Cottrell E.B., Fu R. (2013). Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann. Intern. Med. 158, 114-123.
7. Cooper C., Lester R., Thorlund K., Druyts E., El Khoury A.C., Yaya S., Mills E.J. (2013). Directacting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM. 106, 153-163.
8. Cooper C.L., Druyts E., Thorlund K., Nachega J.B., El Khoury A.C., O'Regan C., Mills E.J. (2012) Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther. Clin. Risk Manag. 8, 105-130.
9. Cure S., Diels J., Gavart S., Bianic F., Jones E. (2012). Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr. Med. Res. Opin. 28, 1841-1856.
10. Diener H.C., Sacco R.L., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., Palesch Y., Martin R.H., Albers G.W., Bath P., Bornstein N., Chan B.P., Chen S.T., Cunha L., Dahlöf B., De Keyser J., Donnan G.A., Estol C., Gorelick P., Gu V., Hermansson K., Hilbrich L., Kaste M., Lu C., Machnig T., Pais P., Roberts R., Skvortsova V., Teal P., Toni D., Vander Maelen C., Voigt T., Weber M., Yoon B.W. (2008). Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 7, 875-884.
11. EASLD. (2012). European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver. Int. 32, 2-8.
12. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. (2011). An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 54, 1433-1444.
13. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. (2009). Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 49, 1335-1374.
14. Greenland S., Longnecker M.P. (1992). Methods for trend estimation from summarized dose-response data, with application to meta-analysis. Am. J. Epidemiol. 135, 1301-1309.
15. Guyatt G.H., Oxman A.D., Kunz R., Brozek J., Alonso-Coello P., Rind D., Devereaux P.J., Montori V.M., Freyschuss B., Vist G., Jaeschke R., Williams J.W., Murad M.H., Sinclair D., Falck-Ytter Y., Meerpohl J., Whittington C., Thorlund K., Andrews J., Schünemann H.J. (2011). GRADE guidelines 6. Rating the quality of evidence-imprecision. J. Clin. Epidemiol. 64, 1283-1293.
16. Guyatt G.H., Oxman A.D., Montori V., Vist G., Kunz R., Brozek J., Alonso-Coello P., Djulbegovic B., Atkins D., Falck-Ytter Y., Williams J.W., Meerpohl J., Norris S.L., Akl E.A., Schünemann H.J. (2011). GRADE guidelines 5. Rating the quality of evidence-publication bias. J. Clin. Epidemiol. 64, 1277-1282.
17. Higgins J.P.T., Green S. (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 Cap. 16.5.4 How to include multiple groups from one study. The Cochrane Collaboration, 2011. Available from www.cochrane- handbook.org.
18. Jacobson I.M., Catlett I., Marcellin P. (2011). Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. EASL 46th Annual Meeting.
19. Kieran J., Schmitz S., O'Leary A., Walsh C., Bergin C., Norris S., Barry M. (2013). The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin. Infect. Dis. 56, 228-235.
20. Lam S.K., Owen A. (2007) Incident diabetes in clinical trials of antihypertensive drugs. Lancet. 369, 1513-1514.
21. Lam S.K., Owen A. (2008). Is the finding of the PROFESS study consistent with predictions of network meta-analysis? Eur. Heart. J. 29, 2580.
22. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 6, e1000097.
23. Montori V.M., Devereaux P.J., Adhikari N.K., Burns K.E., Eggert C.H., Briel M., Lacchetti C., Leung T.W., Darling E., Bryant D.M., Bucher H.C., Schünemann H.J., Meade M.O., Cook D.J., Erwin P.J., Sood A., Sood R., Lo B., Thompson C.A., Zhou Q., Mills E., Guyatt G.H. (2005). Randomized trials stopped early for benefit: a systematic review. JAMA. 294, 2203-2209.
24. Pearlman B.L. (2012). Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect. Dis. 12, 717-728.
25. Poordad F., Bronowicki J.P., Gordon S.C., Zeuzem S., Jacobson I.M., Sulkowski M.S., Poynard T., Morgan T.R., Molony C., Pedicone L.D., Sings H.L., Burroughs M.H., Sniukiene V., Boparai N., Goteti V.S., Brass C.A., Albrecht J.K., Bacon B.R. (2012). Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 143, 608-618.
26. Sitole M., Silva M., Spooner L., Comee M.K., Malloy M. (2013). Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin. Ther. 35, 190-197.
27. Thijs V, Lemmens R, Fieuws S. (2008). Network metaanalysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur. Heart J. 29, 1086-1092.
28. Vierling J., Flamm S., Gordon S. (2011). Efficacy of Boceprevir in Prior Null Responders to Peginterferon/Ribavirin: The PROVIDE Study 62th Annual Meeting of the American Association for the Study of Liver Diseases.
29. WHO. (2013) Regional Office for Europe Hepatitis available at http://www.euro.who.int/en/what-wedo/health-topics/communicable-diseases/ hepatitis accessed on 15 Apr 2013.
30. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., Focaccia R., Younossi Z., Foster G.R., Horban A., Ferenci P., Nevens F., Müllhaupt B., Pockros P., Terg R., Shouval D., van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M. (2011). Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428.